{
    "nct_id": "NCT05307705",
    "official_title": "A Study of LOXO-783 Administered as Monotherapy and in Combination With Anticancer Therapies for Patients With Advanced Breast Cancer and Other Solid Tumors With a PIK3CA H1047R Mutation",
    "inclusion_criteria": "* Have advanced breast cancer or another solid tumor with the presence of a phosphatidylinositol 3-kinase catalytic subunit alpha (PIK3CA) H1047R mutation (or other Sponsor and safety review committee (SRC)-approved, activating PIK3CA mutations other than H1047R mutation)\n* Have adequate archival tumor tissue sample available or be approved by the Sponsor for enrollment if no tumor sample is available.\n* Have stopped all cancer treatment and have recovered from the major side effects\n* Have adequate organ function, as measured by blood tests\n* Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale\n* Patients must have\n\n  * Measurable disease\n\n    --- Patients with non-breast tumor types must have at least 1 measurable lesion\n  * Non-measurable bone disease (at least 1 bone lesion in breast cancer patients only)\n* For patients with an estrogen receptor (ER)+ breast cancer diagnosis:\n\n  * If female, must be postmenopausal\n  * If male, must agree to use hormone suppression\n* Phase 1a:\n\n  -- Dose escalation and backfill patients:\n  * Advanced solid tumor\n  * Patients may have had up to 5 prior regimens for advanced disease\n* Phase 1b:\n\n  * Part A:\n\n    * ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer\n    * Patients may have had up to 5 prior regimens for advanced disease ---- Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required\n  * Part B:\n\n    * ER+/HER2- advanced breast cancer\n    * Patients may have had up to 2 prior regimens for advanced disease.\n  * Part C:\n\n    * ER+/HER2- advanced breast cancer\n    * Patients may have had up to 5 prior regimens for advanced disease.\n\n      ---- Prior CDK4/6 inhibitor therapy required.\n    * Have a diagnosis of diabetes mellitus Type 2\n  * Part D:\n\n    * Advanced breast cancer\n    * Patients may have had up to 5 prior regimens for advanced disease.\n  * Part E:\n\n    * Advanced solid tumor\n    * Patients may have had up to 3 prior regimens for advanced disease advanced disease\n  * Part F:\n\n    * ER+/HER2- advanced breast cancer\n    * Patients may have had up to 5 prior regimens for advanced disease\n\n      * Prior cyclin dependent kinase (CDK)4/6 inhibitor therapy required\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Medical Conditions\n\n  * Colorectal cancer\n  * Endometrial cancers with specific concurrent oncogenic alterations\n  * A history of known active or suspected\n\n    * Diabetes mellitus Type 1 or\n    * Diabetes mellitus Type 2 requiring antidiabetic medication (Phase 1a and all parts of Phase 1b except Part C).\n    * Serious concomitant systemic disorder\n* Known or suspected history of untreated or uncontrolled central nervous system (CNS) involvement.\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection, or other clinically significant active disease process\n* Prior exposure to phosphatidylinositol 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) inhibitor(s), except in certain circumstances",
    "miscellaneous_criteria": ""
}